Merck & Co., Inc.

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2026-02-11 pm EST			5-day change	1st Jan Change
119.31 ^USD	+1.84%		+0.83%	+13.35%

Feb. 11	Sector Update: Health Care Stocks Rise Late Afternoon	MT
Feb. 11	Sector Update: Health Care Stocks Advance Wednesday Afternoon	MT

Merck to Buy Verona Pharma for About $10B

Published on 07/09/2025 at 12:30 pm EDT

MT Newswires

MERCK & CO., INC.

+1.84%

VERONA PHARMA PLC

+0.11%

Merck (MRK) agreed to buy respiratory drugmaker Verona for about $10 billion as part of its ongoing search for ways to fill the Keytruda-sized hole that will emerge over the next few years.

Bloomberg videos, provided by MT Newswires

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	MERCK & CO., INC.	119.31USD	+1.84%	+0.83%	291B
	VERONA PHARMA PLC	106.91USD	+0.11%	-.--%	9.21B

Latest news about Merck & Co., Inc.

Feb. 11	Sector Update: Health Care Stocks Rise Late Afternoon	MT
Feb. 11	Sector Update: Health Care Stocks Advance Wednesday Afternoon	MT
Feb. 11	Sector Update: Health Care	MT
Feb. 11	Daiwa Securities Adjusts PT on Merck & Co. to $120 From $86, Maintains Neutral Rating	MT
Feb. 11	Merck Announces the U.S. Food and Drug Administration Approves KEYTRUDA (Pembrolizumab and Berahyaluronidase Alfa-Pmph) and KEYTRUDA QLEX	CI
Feb. 11	Agilent's Ovarian Cancer Diagnostic Test Receives FDA Clearance	MT
Feb. 11	Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph), plus paclitaxel ± bevacizumab, approved for certain adults with PD-L1+ (CPS ≥1) platinum-resistant ovarian carcinoma as second or third line treatment	RE
Feb. 11	Merck Says US FDA Approves Keytruda Combination in Platinum-Resistant Ovarian Cancer	MT
Feb. 11	Analyst recommendations: Cloudflare, Mattel, Qualcomm, Gilead, Hasbro…
Feb. 10	Merck & Co. Insider Sold Shares Worth $1,202,844, According to a Recent SEC Filing	MT
Feb. 10	FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, primary peritoneal carcinoma	RE
Feb. 10	Rothschild & Co Redburn Adjusts Price Target on Merck & Co. to $140 From $135, Maintains Buy Rating	MT
Feb. 10	Calla Lily Clinical Care and Merck Announce Strategic Collaboration to Advance Intravaginal Drug Delivery Platform	CI
Feb. 09	Merck & Co. Insider Sold Shares Worth $14,485,690, According to a Recent SEC Filing	MT
Feb. 06	Merck & Co. Insider Sold Shares Worth $1,827,992, According to a Recent SEC Filing	MT
Feb. 06	Merck & Co. Insider Sold Shares Worth $765,920, According to a Recent SEC Filing	MT
Feb. 06	Merck & Co. Insider Sold Shares Worth $4,557,025, According to a Recent SEC Filing	MT
Feb. 06	Guggenheim Adjusts Price Target on Merck & Co to $140 From $122, Maintains Buy Rating	MT
Feb. 06	Health Rounds: Women who have had an HPV vaccine need fewer cervical cancer screenings	RE
Feb. 05	Merck veteran Perlmutter-led Eikon ?Therapeutics valued at $860 million in Nasdaq debut	RE
Feb. 05	Merck veteran Perlmutter-led Eikon ?Therapeutics valued at $860 million in Nasdaq debut	RE
Feb. 05	Merck Says Health Canada Approves Enflonsia for Respiratory Syncytial Virus Prevention in Newborns, Infants	MT
Feb. 05	Merck Announces Health Canada Approval of ENFLONSIA for the Prevention of RSV in Newborns and Infants	CI
Feb. 05	Analyst recommendations: Corteva, Snap, Alphabet, Eli Lilly, PayPal, Qualcomm…
Feb. 04	Perlmutter-backed Eikon Therapeutics raises $381.2 million in IPO	RE

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.4%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (20%); - sale of animal health products (9.2%); - other (1.4%). Net sales are distributed geographically as follows: the United States (50.3%), Europe/Middle East/Africa (21.8%), Latin America (5.4%), China (8.6%), Japan (5.1%), Asia/Pacific (4.8%) and other (4%).

Employees

74,000

Sector

Pharmaceuticals

Calendar

Mar. 15 -

More about the company